{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:44:23Z","timestamp":1773704663133,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44 AI157900"],"award-info":[{"award-number":["R44 AI157900"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI142790-02S1"],"award-info":[{"award-number":["U19 AI142790-02S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015595","name":"GHR Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R44 AI157900"],"award-info":[{"award-number":["R44 AI157900"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002570","name":"American Association of Immunologists Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027475","name":"Conrad Prebys Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ebiom.2025.105619","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:57:48Z","timestamp":1740610668000},"page":"105619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-5581","authenticated-orcid":false,"given":"Fernanda","family":"Ana-Sosa-Batiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norazizah","family":"Shafee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Conner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Timis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Maule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithik","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Madany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey Elizabeth","family":"Street","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Zandonatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng Ling","family":"Moi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-8474","authenticated-orcid":false,"given":"Sujan","family":"Shresta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7898","key":"10.1016\/j.ebiom.2025.105619_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105619_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110688","article-title":"Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters","volume":"39","author":"Halfmann","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105619_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","article-title":"T\u00a0cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib7","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S1473-3099(23)00575-3","article-title":"Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant","volume":"23","author":"Uriu","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"7896","key":"10.1016\/j.ebiom.2025.105619_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41586-021-04266-9","article-title":"Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation","volume":"602","author":"Saito","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize\u00a0variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105619_bib10","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41591-023-02521-2","article-title":"Postacute sequelae of COVID-19 at 2 years","volume":"29","author":"Bowe","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2025.105619_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104597","article-title":"Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters","volume":"92","author":"Wouters","year":"2023","journal-title":"eBioMedicine"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib13","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001599","article-title":"Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease","volume":"102","author":"Golden","year":"2021","journal-title":"J\u00a0Gen Virol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105619_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108837","article-title":"Use of convalescent serum reduces severity of COVID-19 in nonhuman primates","volume":"34","author":"Cross","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.ebiom.2025.105619_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69866","article-title":"Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality","volume":"10","author":"Casadevall","year":"2021","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib16","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2666-5247(23)00012-5","article-title":"Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study","volume":"4","author":"Regev-Yochay","year":"2023","journal-title":"Lancet Microbe"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","article-title":"Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity","volume":"53","author":"Ripperger","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib18","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105619_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"6576","key":"10.1016\/j.ebiom.2025.105619_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib22","article-title":"The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice","volume":"4","author":"Ullah","year":"2023","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105619_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-\u03b3R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nature Microbiology"},{"issue":"635","key":"10.1016\/j.ebiom.2025.105619_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105619_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.medj.2022.01.004","article-title":"A\u00a0combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques","volume":"3","author":"Cobb","year":"2022","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105619_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious\u00a0SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105619_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"mAbs"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105619_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity\u00a0for antibody\u2013FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol"},{"issue":"7818","key":"10.1016\/j.ebiom.2025.105619_bib33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection\u00a0of\u00a0human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2025.105619_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105361","article-title":"Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice","volume":"108","author":"Verma","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2025.105619_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115470","article-title":"A\u00a0precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies","volume":"210","author":"Conner","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymeth.2013.07.005","article-title":"Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies","volume":"65","author":"Proetzel","year":"2014","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105619_bib38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nbt.2661","article-title":"Heritable gene targeting in the mouse and rat using a CRISPR-Cas system","volume":"31","author":"Li","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/nprot.2007.145","article-title":"Pronuclear injection for the production of transgenic mice","volume":"2","author":"Ittner","year":"2007","journal-title":"Nat Protoc"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105619_bib40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112421","article-title":"Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence","volume":"42","author":"Hastie","year":"2023","journal-title":"Cell Rep"},{"issue":"47","key":"10.1016\/j.ebiom.2025.105619_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc3582","article-title":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes","volume":"5","author":"Zang","year":"2020","journal-title":"Sci Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105619_bib43","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib44","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1038\/s41467-020-19883-7","article-title":"SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication","volume":"11","author":"Alexandersen","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105619_bib45","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105619_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154461","article-title":"Influenza-specific antibody-dependent phagocytosis","volume":"11","author":"Ana-Sosa-Batiz","year":"2016","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ebiom.2025.105619_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01140-22","article-title":"Characterization of entry pathways, species-specific angiotensin-converting enzyme 2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants","volume":"96","author":"Neerukonda","year":"2022","journal-title":"J\u00a0Virol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105619_bib48","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"issue":"7902","key":"10.1016\/j.ebiom.2025.105619_bib49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.ebiom.2025.105619_bib50","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","article-title":"Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron","volume":"603","author":"Shuai","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105619_bib51","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A\u00a0novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"8\u20139","key":"10.1016\/j.ebiom.2025.105619_bib52","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.molimm.2009.01.026","article-title":"Structural characterization of a human Fc fragment engineered for extended serum half-life","volume":"46","author":"Oganesyan","year":"2009","journal-title":"Mol Immunol"},{"issue":"23","key":"10.1016\/j.ebiom.2025.105619_bib54","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib55","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41467-023-37176-7","article-title":"Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis","volume":"14","author":"Cromer","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib56","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1038\/s41598-022-09999-9","article-title":"Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase","volume":"12","author":"Kodchakorn","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006698","article-title":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus","volume":"13","author":"Hu","year":"2017","journal-title":"PLoS Pathog"},{"issue":"78","key":"10.1016\/j.ebiom.2025.105619_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf1421","article-title":"SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines","volume":"7","author":"Bowen","year":"2022","journal-title":"Sci Immunol"},{"issue":"6546","key":"10.1016\/j.ebiom.2025.105619_bib59","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.abg5268","article-title":"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes","volume":"372","author":"Voss","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2025.105619_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103643","article-title":"Emerging SARS-CoV-2 variants expand species tropism to murines","volume":"73","author":"Shuai","year":"2021","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105619_bib61","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jgg.2021.12.003","article-title":"Evidence for a mouse origin of the SARS-CoV-2 Omicron variant","volume":"48","author":"Wei","year":"2021","journal-title":"J\u00a0Genet Genomics"},{"issue":"7897","key":"10.1016\/j.ebiom.2025.105619_bib62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41586-021-04353-x","article-title":"SARS-CoV-2 infection in free-ranging white-tailed deer","volume":"602","author":"Hale","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105619_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215067120","article-title":"White-tailed deer (Odocoileus virginianus) may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern","volume":"120","author":"Caserta","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1016\/j.ebiom.2025.105619_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bsheal.2021.12.006","article-title":"Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles","volume":"4","author":"Wang","year":"2022","journal-title":"Biosaf Health"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105619_bib66","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"issue":"637","key":"10.1016\/j.ebiom.2025.105619_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"Evans","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6608","key":"10.1016\/j.ebiom.2025.105619_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.abq0203","article-title":"Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines","volume":"377","author":"Bowen","year":"2022","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ebiom.2025.105619_bib69","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants","volume":"386","author":"Yu","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105619_bib70","article-title":"Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection","volume":"3","author":"Jeong","year":"2022","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib71","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3201\/eid2805.220271","article-title":"Cross-variant neutralizing serum activity after SARS-CoV-2 breakthrough infections","volume":"28","author":"Tober-Lau","year":"2022","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib72","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2\u00a0and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib73","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/s41467-023-38275-1","article-title":"Protection against SARS-CoV-2 Omicron BA.4\/5 variant following booster vaccination or breakthrough infection in the UK","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"issue":"31","key":"10.1016\/j.ebiom.2025.105619_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9770","article-title":"Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity","volume":"8","author":"L\u00f3pez-Mu\u00f1oz","year":"2022","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib75","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3390\/v14112378","article-title":"On the need to determine the contribution of anti-nucleocapsid antibodies as potential contributors to COVID-19 convalescent plasma efficacy","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105619_bib76","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/s41467-021-27201-y","article-title":"Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response","volume":"12","author":"Herman","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib77","article-title":"Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy","volume":"3","author":"Herman","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105619_bib78","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105619_bib79","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105619_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110786","article-title":"Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry","volume":"39","author":"Qing","year":"2022","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105619_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159062","article-title":"An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer","volume":"132","author":"Suryadevara","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105619_bib82","article-title":"A\u00a0broadly reactive antibody\u00a0targeting the N-terminal domain of SARS-CoV-2 spike\u00a0confers Fc-mediated protection","volume":"4","author":"Adams","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6591","key":"10.1016\/j.ebiom.2025.105619_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8897","article-title":"Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529","volume":"376","author":"Zhou","year":"2022","journal-title":"Science"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:17:01Z","timestamp":1762618621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":77,"alternative-id":["S2352396425000635"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105619","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105619"}}